Clinical Trials Directory

Trials / Unknown

UnknownNCT04157959

The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia

A Phase I, Single-Center, Open-Label Study to Evaluate Pharmacodynamics of Drug-Drug Interaction Between SHR4640 and Febuxostat in Patients With Hyperuricemia

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
28 (estimated)
Sponsor
Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The objective of the study is to assess the pharmacodynamic properties of drug-drug of SHR4640 and Febuxostat interaction in patients with Hyperuricemia.

Conditions

Interventions

TypeNameDescription
DRUGSHR4640 dose1Tablet,dose1,QD
DRUGFebuxostat dose2Tablet,dose2,QD

Timeline

Start date
2019-10-14
Primary completion
2020-06-01
Completion
2020-06-30
First posted
2019-11-08
Last updated
2019-11-08

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04157959. Inclusion in this directory is not an endorsement.

The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia (NCT04157959) · Clinical Trials Directory